This randomized trial, which was conducted by the NHLBI’s Pediatric
Heart Network, ran from 2007-2011 at 21 clinical centers in the United
States, Canada and Belgium and included 608 patients aged 6 months to 25
years. The two drugs work in different ways. Atenolol works by
relaxing blood vessels and slowing heart rate to improve blood flow and
decrease blood pressure. Losartan also known as Cozaar, blocks the action of certain natural
substances that tighten the blood vessels, allowing the blood to flow
more smoothly and the heart to pump more efficiently.
The results of the Atenolol versus Losartan in Children and Young
Adults with Marfan Syndrome study, supported by NIH’s National Heart,
Lung, and Blood Institute (NHLBI), were presented today at the American
Heart Association (AHA) Scientific Sessions in Chicago. The study was
published simultaneously in the New England Journal of Medicine.
NIH Release
No comments:
Post a Comment